The three-way German coalition that emerged from the 2021 general election has been steadily developing elements of its coalition agreement. A proposal on hybrid DRGs, intended to widen access to services in the outpatient sector, has prompted a white paper from industry.
Much of the content of Germany’s coalition agreement addressing health care and life sciences needs was targeted at the pharma sector. That, and the means of ensuring national resilience in times of a new pandemic or other health care emergency.
However, important proposals hammered out by the Social Democrat (SPD)-led coalition – in which the Green party and business-friendly FDP Liberals are junior parties – in the coalition agreement were...
Less bureaucracy, no more national supply chain law, framework agreements and competition for direct reimbursement of medtech innovations are among the positive changes the local medtech industry might expect as Germany’s new government gets down to work. Life sciences lawyer Gunnar Sachs offers a view from the ground.
A change of government, hospital reform and a drive towards healthcare digitization are keeping German medtech manufacturers on their toes. Making the MDR more user-friendly and winning support for a medtech strategy are arguably bigger priorities. US export tariffs have also pushed their way onto the agenda. BVMed chief executive Marc-Pierre Möll puts it all into context.
Germany’s incoming coalition government has reacted positively to industry’s calls for a dedicated medtech strategy to boost economic growth. Faster digitization, lower energy costs and “IVDR 2.0” are also on the in vitro diagnostic industry’s agenda.
The architect of Germany’s hospital reform, Karl Lauterbach, will not be retained as health minister according to how the new CDU/CSU-SPD coalition government plans to spread the ministerial portfolios.
